Kartos Therapeutics, Inc. (United States)

Alternate names: Kartos Therapeutics, Kartos Therapeutics, Inc., Kartos Theraputics

ROR: 01evecd82

OpenAlex ID: I4405267160

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

2022 · Carrie L. Kitko, Mukta Arora, et al. · Journal of Clinical Oncology · 106

PDF

BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis

2022 · Srdan Verstovsek, Haifa Kathrin Al-Ali, et al. · Future Oncology · 46

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

2021 · Pankit Vachani, Andrzej Lange, et al. · Blood · 23

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024

2024 · Jason Gotlib, Aaron T. Gerds, et al. · Journal of the National Comprehensive Cancer Network · 20

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis

2024 · John O. Mascarenhas, Viola Maria Popov, et al. · Blood · 19

PDF

Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC).

2022 · Michael K.K. Wong, Melissa Amber Burgess, et al. · Journal of Clinical Oncology · 17

Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes

2024 · Tapan M. Kadia, Meixian Huang, et al. · NEJM Evidence · 15

Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives

2023 · Ivan Krecak, Srdan Verstovsek, et al. · Annals of Hematology · 12

Phase 1 Concentration‐QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT‐232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia

2021 · Adekemi Taylor, Dana Lee, et al. · Clinical Pharmacology in Drug Development · 12

PDF

S210: an Open-label, Global, Phase (ph) 1b/2 Study Adding Navtemadlin (nvtm) to Ruxolitinib (rux) in Patients (pts) With Primary or Secondary Myelofibrosis (mf) Who Have a Suboptimal Response to Rux

2023 · John Mascarenhas, Tania Jain, et al. · HemaSphere · 11

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

2024 · John O. Mascarenhas, Prithviraj Bose, et al. · Blood · 10

PDF

An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

2020 · John Mascarenhas, Alessandro M. Vannucchi, et al. · Blood · 10

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

2019 · Jason Gotlib, Nashat Gabrail, et al. · Blood · 10

Navtemadlin (KRT-232), a Small Molecule MDM2 Inhibitor, Is More Effective Than Decitabine Against Myeloproliferative Neoplasm-Blast Phase in a Patient-Derived Xenograft Model

2021 · Xiaoli Wang, Cing Siang Hu, et al. · Blood · 9

BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).

2021 · Srdan Verstovsek, Haifa Kathrin Al-Ali, et al. · Journal of Clinical Oncology · 9

KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti–PD-1/L1 immunotherapy.

2020 · Michael K.K. Wong, Ciara Marie Kelly, et al. · Journal of Clinical Oncology · 8

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

2024 · Pankit Vachhani, Raajit Rampal, et al. · Blood · 7

PDF

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

2019 · Regina Garcia-Delgado, Donal P. McLornan, et al. · Blood · 7

Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity

2019 · Allard Kaptein, Terry Podoll, et al. · Cancer Research · 7

Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms.

2023 · Ivan Krecak, Srdan Verstovsek, et al. · PubMed · 6

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib

2026 · Pankit Vachhani, Abdulraheem Yacoub, et al. · Future Oncology · 5

Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT‐232) in Fed and Fasted Healthy Subjects

2022 · Shekman Wong, Cecile Krejsa, et al. · Clinical Pharmacology in Drug Development · 5

A Phase 1b/2 Study of Navtemadlin (KRT-232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed/Refractory, TP53WT, Ph+ Chronic Myeloid Leukemia

2021 · Jorge E. Cortes, Omer Hassan Jamy, et al. · Blood · 5

S214: Disease-modifying Activity of Navtemadlin (nvtm) Correlated With Survival Outcomes in Janus Kinase Inhibitor (jaki) Relapsed or Refractory (r/r) Myelofibrosis (mf) Patients (pts)

2023 · Pankit Vachhani, Andrew Perkins, et al. · HemaSphere · 4

P991: Adding Navtemadlin (nvtm) to Ruxolitinib (rux) Potentiates Apoptosis in Myeloblasts From Patients (pts) With Myelofibrosis (mf)

2023 · Tracy Clevenger, Jean Cheung, et al. · HemaSphere · 4

Works count: 53

Citation count: 1,324